BeOne Medicines Ltd.
Close on Nov 20, 2026Market cap $44.45BP/E 69.9Yield –
BeOne Medicines Collaboration Right-to-Access IP Revenue by Quarter
Collaboration Right-to-Access IP Revenue ($M, FY19–FY22) ($M)
BeOne Medicines Collaboration Right-to-Access IP Revenue: $52M in Q3 2023, up 98.5% from a year earlier. That is the highest of the 11 quarters on record here. No newer figure appears in the documents we track.
Where the Q3 2023 figure comes from
Source: Form 10-Q (filed 2023-11-09) ↗
Reported in Form 10-Q / 10-K Collaboration Note.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Collaboration Right-to-Access IP Revenue ($M, FY19–FY22) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2023 | Sep 30, 2023 | 52 | +98.5% | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2023 | Jun 30, 2023 | 26.2 | 0.0% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 26.2 | 0.0% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2022 | Dec 31, 2022 | 26.2 | +555.0% | Form 10-K (filed 2023-02-27) ↗ |
| Q3 2022 | Sep 30, 2022 | 26.2 | – | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 26.2 | – | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | 26.2 | – | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 4 | – | Form 10-K (filed 2023-02-27) ↗ |
| Q3 2021 | Sep 30, 2021 | 0 | – | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2021 | Jun 30, 2021 | 0 | – | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2021 | Mar 31, 2021 | 0 | – | Form 10-Q (filed 2022-05-09) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Collaboration Right-to-Access IP Revenue ($M), quarterly Q1 2021–Q3 2023 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rev-collab-ip-access
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.
See a number that looks wrong?